Chapter 47. Lymphocyte Predominant Hodgkin Lymphoma

  1. Mark A. Crowther MD, MSc, FRCPC Professor Division Director3,4,
  2. Jeff Ginsberg MD, FRCPC Professor5,
  3. Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor6,7,
  4. Ralph M. Meyer MD, FRCPC Director Professor8,9 and
  5. Richard Lottenberg MD, FACP Professor10
  1. Brandon McMahon MD1 and
  2. Jonathan W. Friedberg MD2

Published Online: 4 FEB 2009

DOI: 10.1002/9781444300857.ch47

Evidence-Based Hematology

Evidence-Based Hematology

How to Cite

McMahon, B. and Friedberg, J. W. (2008) Lymphocyte Predominant Hodgkin Lymphoma, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch47

Editor Information

  1. 3

    Division of Hematology, McMaster University, Hamilton, Ontario, Canada

  2. 4

    St. Joseph's Hospital, Hamilton, Ontario, Canada

  3. 5

    Department of Medicine, McMaster University, Hamilton, Canada

  4. 6

    CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

  5. 7

    McMaster University, Hamilton, Canada

  6. 8

    National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada

  7. 9

    Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada

  8. 10

    Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Author Information

  1. 1

    Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, USA

  2. 2

    James P. Wilmot Cancer Center, University of Rochester, Rochester, New York, USA

Publication History

  1. Published Online: 4 FEB 2009
  2. Published Print: 27 JUN 2008

ISBN Information

Print ISBN: 9781405157476

Online ISBN: 9781444300857

SEARCH

Keywords:

  • Lymphocyte predominant Hodgkin lymphoma (LPHL);
  • literature-search strategy and inclusions;
  • LPHL - distinct clinical/pathologic entity from classical HL;
  • de novo LPHL and classical Hodgkin lymphoma treatment;
  • detection and treatment of LPHL progression or relapse;
  • rituximab - included as “standard” therapeutic modality for LPHL;
  • rituximab - active agent in LPHL

Summary

This chapter contains sections titled:

  • Introduction

  • Questions

  • Literature-search strategy and inclusions

  • Is LPHL a distinct clinical/pathologic entity from classical HL?

  • Should de novo LPHL be treated differently from classical Hodgkin lymphoma?

  • Should detection and treatment of LPHL progression or relapse be different from classical Hodgkin lymphoma?

  • Should rituximab be included as “standard” therapeutic modality for LPHL?

  • Recommendation

  • Acknowledgments

  • References